^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ERBB4 expression

    i
    Other names: ERBB4, ALS19, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4, HER4
    Entrez ID:
    2066
    Related biomarkers:
    Mutation
    Others
    11ms
    Transcriptomic analysis of ROS1+ non-small cell lung cancer reveals an upregulation of nucleotide synthesis and cell adhesion pathways. (PubMed, Front Oncol)
    The upregulation of GJB2 may serve as a prognostic biomarker, along with IL20RB, a known mediator of bone metastases. Furthermore, TDFP1 and ISL1 were identified as relevant transcription factors that could potentially regulate the biological processes in ROS1-rearranged NSCLC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NOTCH1 (Notch 1) • CD74 (CD74 Molecule) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • CLTC (Clathrin Heavy Chain) • IL20RB (Interleukin 20 Receptor Subunit Beta)
    |
    PD-L1 expression • ERBB3 expression • ROS1 rearrangement • ERBB3 overexpression • CD74 expression • ERBB4 expression
    1year
    METTL3 and HERC4: Elevated Expression and Impact on Hepatocellular Carcinoma Progression. (PubMed, Cancer Biother Radiopharm)
    Besides, HERC4 overexpression reversed the effects of METTL3 silencing on the proliferation and migration as well as the levels of angiogenic factors in HCC cells. This study reveals the upregulation of METTL3 and HERC4 expression in HCC and their role in HCC by enhancing the proliferation, migration, and angiogenesis potential of HCC cells.
    Journal
    |
    VIM (Vimentin) • FGF (Fibroblast Growth Factor) • CDH2 (Cadherin 2) • METTL3 (Methyltransferase Like 3) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    VIM expression • ERBB4 expression
    1year
    Extraordinary therapeutic effect of PSMA radioligand therapy in treatment-refractory progressive metastatic prostate cancer with the transketolase inhibitor benfo-oxythiamine as a radiosensitizer-A case report. (PubMed, Front Med (Lausanne))
    Although the patient had experienced massive progression before the first cycle of B-OT-PRLT, he survived for an additional 12 months. This case supports the hypothesis that B-OT-PRLT could overcome radiation resistance in prostate cancer patients who do not initially respond to 177Lu- or 225Ac-PRLT.
    Journal • Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 positive • ERBB4 expression
    1year
    The role and mechanism of NRG1/ErbB4 in inducing the differentiation of induced pluripotent stem cells into cardiomyocytes. (PubMed, BMC Cardiovasc Disord)
    In conclusion, promoting the expression of NRG1/ErbB4 induced the differentiation of iPSC into cardiomyocytes, possibly through modulation of the PI3K/Akt signaling pathway.
    Journal
    |
    NRG1 (Neuregulin 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    AKT1 overexpression • ERBB4 expression
    |
    LY294002
    1year
    Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    ERBB3 expression • ERBB4 expression
    |
    tamoxifen
    1year
    HER4 is a high-affinity dimerization partner for all EGFR/HER/ErbB family proteins. (PubMed, Protein Sci)
    The interaction between HER4 and other HER family members intensified in the presence of a HER4-specific ligand. Our work suggests that HER4 is a preferred dimerization partner for all HER family proteins, even in the absence of ligands.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    ERBB4 expression
    over1year
    Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Medical College of Wisconsin
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    ERBB3 expression • ERBB4 expression
    |
    tamoxifen
    almost2years
    Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. (PubMed, Int J Mol Sci)
    Finally, proteomic analysis confirmed a significant change in the abundance patterns of more than 600 proteins with implications in key biological processes, such as ribosome formation, mitochondrial activity, and metabolism, which could be relevant mechanisms in the generation of resistance in HER2-positive breast cancer. We concluded that these resistant BCCLs may be a valuable tool to better understand the mechanisms of acquisition of resistance to trastuzumab and pertuzumab-based anti-HER2 therapy.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    HER-2 positive • HER-2 overexpression • HER-2 mutation • ERBB4 expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    2years
    Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. (PubMed, BMC Cancer)
    In RAS wt mCRC patients receiving EGFR-targeted therapy, BRAF mutation is a powerful prognostic and therapy-predictive biomarker, with no effect found for PIK3CA mutation, PTEN mutation or deletion, but the combined biomarker KRAS/NRAS/BRAF/PIK3CA mutations predict resistance to anti-EGFR therapy. Low miR-31-3p expression may have positive prognostic and therapy predictive effects. Evidence on the prognostic and predictive roles of EGFR and its ligands, and HER2/3/4 is insufficient.
    Retrospective data • Review • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • EREG (Epiregulin) • MIR31 (MicroRNA 31)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • HER-2 expression • PTEN mutation • ERBB3 expression • RAS mutation • RAS wild-type • ERBB3 mutation • PIK3CA mutation + PTEN mutation • AREG expression • ERBB4 expression • KRAS deletion
    2years
    Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells (ASH 2023)
    Our data additionally show that NK cell-based immunotherapy may be able to promote the functionality of the patient's own T cells, demonstrating how our ex vivo modeling approach can help to refine the mechanism of action of immunotherapies. Our work paves the way for identifying subgroups of AML patients responding to NK cell-based immunotherapies.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • FASLG (Fas ligand) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TNFRSF18 (TNF Receptor Superfamily Member 18) • TNFSF10 (TNF Superfamily Member 10) • HLA-C (Major Histocompatibility Complex, Class I, C) • IRF7 (Interferon Regulatory Factor 7) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2) • MX1 (MX Dynamin Like GTPase 1)
    |
    ERBB4 expression